No headlines found.
No press releases found.
No news found.
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. The company operates in one operating segment which is clinical research.
Onkure Therapeutics - Class A trades on the NASDAQ stock market under the symbol OKUR.
As of February 27, 2026, OKUR stock price climbed to $2.71 with 134,607 million shares trading.
OKUR has a beta of 1.84, meaning it tends to be more sensitive to market movements. OKUR has a correlation of 0.17 to the broad based SPY ETF.
OKUR has a market cap of $36.72 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that OKUR belongs to (by Net Assets): VTI, VXF, IWC, AVTM.
OKUR has underperformed the market in the last year with a return of -44.6%, while the SPY ETF gained +18.5%. In the last 3 month period, OKUR fell short of the market, returning -5.2%, while SPY returned +1.2%. However, in the most recent 2 weeks OKUR has outperformed the stock market by returning +12.0%, while SPY returned +0.6%.
OKUR support price is $2.50 and resistance is $2.83 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OKUR shares will trade within this expected range on the day.
